Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Receivables (2024 - 2025)

Korro Bio's Receivables history spans 2 years, with the latest figure at $1.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Receivables fell 41.04% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Dec 2025, down 41.04%, and an annual FY2025 reading of $1.0 million, down 41.04% over the prior year.
  • Receivables for Q4 2025 was $1.0 million at Korro Bio, up from $800000.0 in the prior quarter.
  • The five-year high for Receivables was $10.0 million in Q3 2024, with the low at $800000.0 in Q3 2025.